Compare NTGR & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTGR | BBOT |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.7M | 605.6M |
| IPO Year | 2000 | N/A |
| Metric | NTGR | BBOT |
|---|---|---|
| Price | $23.11 | $8.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $39.00 | $24.00 |
| AVG Volume (30 Days) | 317.8K | ★ 526.7K |
| Earning Date | 04-29-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.00 | $7.00 |
| 52 Week High | $36.86 | $14.87 |
| Indicator | NTGR | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 55.98 |
| Support Level | $22.92 | $8.02 |
| Resistance Level | $25.06 | $9.50 |
| Average True Range (ATR) | 0.93 | 0.57 |
| MACD | 0.11 | 0.11 |
| Stochastic Oscillator | 68.16 | 58.76 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.